1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Evaluation of the European Society of Cardiology/European Respiratory Society derived three-and four-strata risk stratification models in pulmonary arterial hypertension : Introducing an internet-based risk stratification calculator
(
- Contribution to journal › Article
- 2022
-
Mark
Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
Bioactive adrenomedullin for assessment of venous congestion in heart failure
(
- Contribution to journal › Article
- 2021
-
Mark
Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2020
-
Mark
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy : a registry-based study
(
- Contribution to journal › Article
- 2014
-
Mark
Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension
(
- Contribution to journal › Article